dc.contributor.author | Firat, D | |
dc.contributor.author | Akbulut, H | |
dc.contributor.author | Demirkazik, A | |
dc.contributor.author | Ozet, A | |
dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Ozguroglu, M | |
dc.contributor.author | Icli, F | |
dc.contributor.author | Celik, I | |
dc.contributor.author | Aykan, F | |
dc.contributor.author | Uner, A | |
dc.date.accessioned | 2021-03-05T19:58:19Z | |
dc.date.available | 2021-03-05T19:58:19Z | |
dc.date.issued | 1998 | |
dc.identifier.citation | Icli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A., Ozguroglu M., Tas F., Akbulut H., Firat D., "A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.", Cancer, cilt.83, ss.2475-80, 1998 | |
dc.identifier.issn | 0008-543X | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_d1c3188c-7638-4af5-a056-d013cffda3db | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/138638 | |
dc.description.abstract | BACKGROUND, Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with advanced gastric carcinoma (AGC) | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Onkoloji | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.title | A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. | |
dc.type | Makale | |
dc.relation.journal | Cancer | |
dc.contributor.department | , , | |
dc.identifier.volume | 83 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 2475 | |
dc.identifier.endpage | 80 | |
dc.contributor.firstauthorID | 121846 | |